

Rallying a Community

When the Rotz family first came to Penn Medicine's Abramson Cancer Center in July 2012, Kathleen "Kathy" Rotz's stage IV non-small cell lung cancer had spread to her brain, demanding a rigorous and innovative combination of therapies. Defying the odds, Kathy would survive twenty-five months before passing away in August of 2014.

And, that time was precious. Kathy was determined to live each day to the fullest, even running a 5K while battling her cancer—inspiring her family to help make a difference for others facing a difficult diagnosis.

Just as Kathy's medical team helped her family feel prepared and confident in her care, sharing "We are part of your family now," the Rotz family is helping to bring that sentiment to others.

In 2015, Chris and the Rotz children Megan, Kaitlan, and Christopher Jr. organized the first annual **Kathleen M. Rotz Lung Cancer Research Fund Annual 5K Run/Walk** to bring together their community and fuel lung cancer research at the Abramson Cancer Center.

Today, the Rotz family's run/walk draws nearly 300 supporters and has raised almost \$200,000 for the lung cancer team at Penn—numbers that far surpass their initial dreams.

To Chris, the tangible value of lung cancer research at Penn is a crucial factor in their ability to rally a community. Each of the volunteers and donors who participate in the 5K knows that they are an important part of powering innovative research at Penn – research that the Rotz family credits with giving Kathy the tools she needed to extend her life.

While the Kathleen M. Rotz Lung Cancer Research Fund Annual 5K Run/Walk supports the heart of the Fund's mission—finding a cure to lung cancer—the Rotz family has also found a way to celebrate Kathy's legacy during her favorite time of year: Christmas.

Each year, the Rotz family organizes **Believe in the Magic of Santa**, an annual gift giving event at the **Abramson Cancer Center at Penn Presbyterian Medical Center**. In collaboration with Penn social worker Dolan A. Kneafsey, LSW, MSS, the Rotz family distributes gift cards and presents from holiday "wish lists" to underserved cancer patients and their families.



Christopher Rotz, pictured with children Megan, Kaitlan, and Christopher Rotz, Jr.

“The fund itself is the true gift to me – that we are able to support lung cancer research to improve people's lives through innovation and hope.”

— Christopher Rotz

Believing firmly that the magic and joy of the holiday season should not be deterred by illness, the program seeks to ease financial burdens and restore a sense of normalcy to those affected by cancer during the holiday season.

Kathy's legacy—her dedication, warmth, and thoughtfulness—is reflected in the ultimate hope that underpins both of the Rotz family's annual events: that no one should be alone in their journey with cancer.

Leveraging Philanthropy

Philanthropy makes a substantial impact on the ACC's research efforts. This crucial support pilots innovative, early-stage ideas, so researchers can generate valid data through preclinical studies. Once the findings show promise, physician-scientists are able to obtain funding from government entities such as the National Cancer Institute (NCI)—enabling them to achieve a wider impact and ultimately transform patient care in the clinics.

Philanthropic support like the Rotzs' empowered the ACC's **Thoracic Oncology Translational Center of Excellence** to receive a \$10.7 million grant from the NCI to advance strategies for adapting CAR-T cells in solid tumors. Sponsoring five years of research across three interconnected projects, this

continues on page 2





A MESSAGE FROM THE DIRECTOR

I never cease to be amazed by the power of coming together as a community in the fight against cancer. This issue of Penn's *Abramson Report* includes stories of some of the many people who are helping us bring hope to those facing cancer.

You will read about how grassroots communities can help accelerate novel research and translate findings from the laboratory to ultimately transform patient care.

Our leadership volunteers and fundraising partners are integral to our community, as well. We are excited to share recent changes within our volunteer leadership that will continue to invigorate our community. And, you will read how the foresight and passion of one family continues to stimulate exciting scientific discoveries and make a global impact.

This impact is felt beyond the patients we treat at our facilities. See how collaborations between pediatric and adult cancer researchers ensure that we explore the potential of scientific discovery for both children and adults. That is the Power of Penn.

Thanks to this diverse community of partners, our ImmunoRevolution continues to change the landscape of cancer care. We celebrate new milestones every day, including four new FDA approved therapies in 2018 alone.

Be sure to read about upcoming events, many of which are hosted by our community partners across the greater Philadelphia area.

From patient advocates and volunteers, to fundraisers and research collaborators, our expansive community pushes us to achieve more every day. Thank you for choosing to stand side by side with us as members of the Abramson Cancer Center community.

Robert H. Vonderheide, MD, DPhil
John H. Glick, MD, Abramson Cancer Center Director's Professor
Director, Abramson Cancer Center

continued from previous page

Leveraging Philanthropy

grant supports the optimization of CAR-T cell strategies in lung cancer, including exploration of combination therapies and questions of safety and durability. This is the power of a collective community.

Another beneficiary of philanthropy, Penn Medicine's **Liquid Biopsy Initiative** is collaborating across the Abramson Cancer Center and Penn's Campus to develop new diagnostic tools that will forever change the course of cancer care.

Liquid biopsy is a test that helps doctors better diagnose patients and choose, monitor, and modify their treatments—all with a simple blood draw. Less invasive than traditional biopsies of tumor tissue, liquid biopsies are a highly precise method of diagnosing patients and informing treatment plans on a more frequent basis. At Penn Medicine, the ever-expanding number of targeted therapies for our patients has been accompanied by a need for this precise, and real-time diagnostic.

The Liquid Biopsy Initiative is already having a profound effect on lung cancer patients at Penn's Abramson Cancer Center. Philanthropy is crucial in allowing research such as these efforts to ultimately benefit more patients at Penn and beyond.

To support lung cancer research, contact Christian Hyde at (215) 573-0240 or hydec@upenn.edu

Welcoming New Leadership

As we approach one year out from the public launch of the Power of Penn Campaign, we are excited to announce several changes to our strategic volunteer leadership that will continue to invigorate the Penn community.



Richard S. Schiffrin, Esq. has been appointed Chair of the **Abramson Cancer Center Director's Leadership Council (ACCDLC)**, replacing outgoing chair, Richard Vague. As an advocate for the cutting-edge research at Penn Medicine, Richard has brought his professional expertise and philanthropic partnership to the ACCDLC since 2010. In 2016, Richard, and wife Barbara Schiffrin, PsyD, created the **Richard and Barbara Schiffrin President's Distinguished Professorship**—currently held by **E. John Wherry, PhD**, Chair of Systems Pharmacology and Translational Therapeutics.



Richard W. Vague will take on a new role as Chair of the ACC's newly established **Innovation Advisory Board**, a strategic corporate volunteer board which will partner on innovative projects, campaign initiatives, and deepening the ACC's philanthropic and volunteer network. At the University level, Vague will assume the role of *The Power of Penn Medicine* Campaign and Campaign Cabinet Chair from George Weiss, who will be stepping down. A Trustee and member of the University Development Committee, Richard is a longtime supporter of Penn Medicine, establishing the **Richard W. Vague Professorship in Immunotherapy**—currently held by CAR-T pioneer, **Carl H. June, MD**.



Mindy Gray has extended her philanthropic leadership on the Penn Medicine Board and assumed Richard Vague's seat as Vice Chair of Research for *The Power of Penn Medicine* Campaign and Campaign Cabinet. In 2012, Mindy, and her husband Jon Gray, established the **Basser Center for BRCA** at the Abramson Cancer Center. Basser is the first and foremost comprehensive center for innovative research, treatment, and prevention for BRCA-related cancers. Mindy is currently Chair of the Basser Center Leadership Council and emeritus member of the ACCDLC.

Recognizing Global Impact

Basser Center for BRCA

The Basser Center for BRCA funds innovative clinical and translational research projects—at Penn and around the world—to advance the care of individuals with a *BRCA1/2* mutation. Given annually to a scientist who has significantly impacted this field with their research, **Shari and Len Potter** established and endowed the Basser Global Prize in order to remove the constraints that can limit visionary scientists from driving their innovative research forward.

To date, six scientists have been recognized for their diverse, impactful research contributions, receiving unrestricted support in order to accelerate their efforts.

Maria Jasin, PhD is the recipient of the 2018 Basser Global Prize, and will give the keynote at the annual Basser Center Symposium on May 7, 2019. In her research, Dr. Jasin aims to gain insight into *BRCA1/2*-related cancers by studying double-strand break repair and genomic integrity, and their relationship to tumor suppression. Like the recipients before her, Dr. Jasin's research has been fundamental in strategies for the treatment of BRCA-related cancers. Support from the Basser Global Prize is enabling Dr. Jasin to continue to contribute to a better understanding of BRCA mutations, accelerating more effective and personalized treatment plans.

At Penn Medicine and the Basser Center, advancements in the treatment and care of BRCA-related cancers are a result of these powerful, collaborative partnerships between committed, talented researchers, generous partners, and brave patients and families.

Learn More: basser.org



MARIA JASIN, PHD

Home Program: Developmental Biology at Memorial Sloan Kettering Cancer Center

Academic Post: Professor, Weill Graduate School of Medical Sciences at Cornell University

Education: PhD, Massachusetts Institute of Technology; postdoctoral work at University of Zurich and Stanford University

Research Expertise: Tumor Suppression; Double-Strand Break Repair; Genomic Integrity

Register Now:

5th Annual Breakthroughs and Discoveries Panel
May 7 | Philadelphia, PA | basser.org/discoveryevent

Save the Date:

Basser Jean Bash | November 18, 2019
Cipriani Wall Street | New York, NY

Abramson Family Cancer Research Institute (AFCRI) Update

Powering Medical Discovery

Penn Medicine's basic science research enterprise is the engine powering the Abramson Cancer Center. Many of our questions and answers originate at the AFCRI, where researchers and physicians work collaboratively to translate novel discoveries into personalized therapies to benefit cancer patients throughout the world.

Philanthropic partners like **Marc and Jackie Topaz**, and **David and Rhonda Kessler**, who established the Topaz-Kessler Equipment Fund, enable the AFCRI and the Department of Cancer Biology (DCBIO) to strategically invest in vital, shared laboratory resources. Philanthropy helps to maintain a competitive edge in the field of cancer research and continue to accelerate promising new therapies.

Over the course of 10 years, the Topaz-Kessler Fund has enabled the purchase of equipment with diverse applications, including the ability to monitor cell proliferation in real-time; the measurement of nutrients in cell culture media for an understanding of metabolic characteristics in cells; the ability

"Critical technology such as this allows the most promising investigators to implement breakthrough experimental strategies that change the way we think about, understand, and treat cancer."

— M. Celeste Simon, PhD
Scientific Director, AFCRI



to sort human cell lines without manual oversight; and high-throughput cell analysis with real-time data acquisition.

Thanks to partners like the Topaz and Kessler families, the AFCRI is able to continue stimulating new discoveries ahead of their time. From alleviating sample backlogs to permitting time-sensitive experiments to move forward, this new state-of-the-art equipment has already proven vital to powering research at the AFCRI.

Penn's ImmunoRev

For decades, Penn Medicine's Abramson Cancer Center has been amassing an immunological arsenal. Building and testing cancer therapies that weaponize the immune system on several fronts: turning it on, releasing its brakes, rejuvenating it, or programming it to hunt and kill cancer.

This is nothing short of a revolution in care.



“The miracle isn't about me personally. Whether I live or die is a speed bump in history. The miracle is that my body was a platform to discover a treatment that literally could save thousands of lives. Wow. That's what blows me away.”

—Lt. Col. David “Bo” Bolgiano,
Radvax Patient

Immune Monitoring: The Next Great Leap

No two immune systems are alike—each has its own **unique fingerprint**. And yet, we treat diseases with drugs designed for everybody.

Imagine, going to your doctor and getting an **immune work-up** as part of your annual physical. Imagine, having your immune health **monitored by your physician** like your cholesterol levels and blood pressure.

When facing a new diagnosis, a physician could use your **fingerprint** to develop an **immune health report**, helping to pick the most precise treatment for you.

Human immune monitoring is immunology's **next great leap**, and could change the way we prevent and treat countless diseases.

This is the Power of the Penn Collective.

Bringing Research to Life

Immunotherapies include T-cell therapies, vaccines, checkpoint inhibitors, and monoclonal antibodies—given alone or in combination with surgery, radiation, targeted therapy, stem cell chemotherapy, or other forms of immunotherapy.

At Penn Medicine, we have a proud history of advancing the front line of our ImmunoRevolution:

Penn **melanoma** patients participated in the very first phase I trial of targeted immune checkpoint inhibitor Keytruda®, as well as concurrent phase II and phase III studies.

Developed “**RadVax**,” a combination therapy of radiation and anti-CTLA4 antibody ipilimumab that boosts the effects of immunotherapy and bolsters the immune system against cancer.

Led first in human trial of BCMA monoclonal antibody for **multiple myeloma**, with additional research looking at combination CAR-T/BCMA effectiveness.

Ushered chimeric antigen receptor (CAR-T) cell therapy to become the first FDA-approved personalized gene therapy for blood cancers such as **acute lymphocytic leukemia** and **non-Hodgkin's lymphoma**.

Moved beyond CD19 (the Kymriah® target) to find new CAR targets, such as CD22—which is found in 90% of acute lymphocytic leukemia cells.

Completed phase I trial for CAR-T in **recurrent glioblastoma**, and developed phase I trial for combination strategies with CAR-T/PD-1 inhibitors for **glioblastoma with newly diagnosed mutation**.

volution

Our battles have been bolstered by benefactors and ambassadors whose support has moved immunotherapies from last resort treatments to upfront therapies.

“The University of Pennsylvania ignited the **ImmunoRevolution**. Research discoveries within the Abramson Cancer Center are traversing our health system and campus. This Penn Power is changing the way we treat patients—with cancer and beyond.”

—Robert H. Vonderheide, MD, DPhil
*John H. Glick, MD ACC Director's Professor
Director, Abramson Cancer Center*

CAR-T Cell Therapy

The 20 year, overnight success of CAR-T therapy began as all revolutionary therapies do: with a basic science discovery. The deeper understanding of lymphocytes uncovered within the **Abramson Family Cancer Research Institute** was one of the first sparks that ignited Penn's ImmunoRevolution.

Penn's ImmunoRevolution is expanding. CAR-T cell technology currently directs T-cells to kill cancer cells. Can we instruct T-cells to protect cells in the body *against* the immune system? Or make T-cells agents of change, rather than killers?

Physician-scientists are collaborating across disciplines to find out. Together, they are translating CAR-T's successes in blood cancer to advancements in solid tumor cancers, as well as other diseases.

Penn is fighting these battles on all fronts:

CANCER

Acute myeloid leukemia, advanced refractory thyroid, breast, chronic lymphocytic leukemia, kidney, lung, myeloma, melanoma, neuroendocrine tumors, non-Hodgkin lymphoma, ovarian, pancreatic, prostate, and recurrent glioblastoma.

BEYOND CANCER

Autoimmunity disease like Pemphigus vulgaris and Type 2 diabetes, heart disease, hemophilia A, and neurodegenerative disorders such as Parkinson's.

Collaborative culture

INFRASTRUCTURE

Excellence in immunotherapy

RICH TRAINING GROUND

Core understanding in cellular engineering

Extensive knowledge base in specialties

Established project-based databases within the **Thoracic Oncology Translational Center of Excellence** to track patient response and acquired resistance to immunotherapies.

Multiple studies seek to understand why immunotherapies do not work for all patients, determine the body's mechanisms of resistance to treatment, and improve outcomes by predicting response.

Rewiring macrophages—immune cells capable of “eating” cancer cells—to overcome CD47 signal expression and attack **solid tumors in cancers such as pancreatic or colon.**

Advancing T-cell therapy using next-generation DNA sequencing strategies to create **personalized vaccines** for numerous types of cancer.

Opened clinical trials employing gene editing technology such as CRISPR with T-cell therapy to treat **multiple myeloma, sarcoma, acute myeloid leukemia, and melanoma.**

Adapting anti-PD-1 therapies to boost immune response to cancer cells in cancers beyond melanoma—including **mesothelioma, head and neck, non-small cell lung, triple-negative breast, and ovarian cancers.**

Developing a novel, preventative “smallpox vaccine” for BRCA mutation carriers to dramatically reduce the onset of **BRCA1/2-related breast, pancreatic, ovarian, and colon cancers.**

Putting Children First Focus on Pediatric Cancer Research

“Everything is within a three-to-four minute walk,” explains **Stephen Hunger, MD**, describing the ease with which pediatric and adult cancer researchers at Penn are able to share knowledge and exchange ideas with one another. Dr. Hunger is Associate Director for Pediatric Research within the Abramson Cancer Center, appointed in 2018 to replace **Garrett Brodeur, MD** – whose years of leadership helped shape and grow children’s cancer research at Penn.

Within the field of pediatric oncology, Penn is historically known for research in neuroblastoma, a rare childhood cancer that begins in the nerve tissue of the adrenal glands, neck, spine, abdomen, or chest. In recent years, the program’s successful treatment of leukemia with CAR-T cell therapy has made headlines. Overall, leukemias represent one-third of the cancers treated at Children’s Hospital of Philadelphia (CHOP), where Penn’s pediatric researchers are based. Brain tumors comprise another 20 to 25 percent.

“It’s very important to understand how pediatric cancers differ from adult cancers, and how that drives our therapeutic opportunities,” Dr. Hunger explains. For example, acute lymphoid leukemia looks completely different at a clinical and genomic level in adults versus children. The same treatments do not have the same impact. As a result, there is much insight to be gained from an environment where researchers address the similarities and differences between pediatric and adult cancers collaboratively.

Dr. Hunger sees a future in even greater integration of adult and childhood cancer research at the Abramson Cancer Center. Proximity makes this possible. The children’s hospital is next door to the adult hospital, and within blocks of medical research buildings, the Wharton School of Business, the Nursing School, and Penn’s nine other schools. This dynamic environment promotes discovery in basic, translational, clinical, and behavioral research.

“Pediatric researchers are trying to better understand the molecular events that drive cancer and attack those directly. We want to improve cure rates and reduce side effects.”

— **Stephen Hunger, MD**

Professor of Pediatrics | Perelman School of Medicine

Jeffrey E. Perelman Distinguished Chair in the Department of Pediatrics | Children’s Hospital of Philadelphia

Groundbreaking Studies Seek Big Answers

What role does genetics play in children’s cancers?

John Maris, MD, Giulio D’Angio Endowed Professor, discovered a genetic link to neuroblastoma and, along with **Yael Mosse, MD**, Associate Professor, is developing targeted therapies to treat the disease.

Why do the immune systems of some children fail to recognize and attack cancer?

David Barrett, MD, PhD, Assistant Professor, studies immune response in pediatric cancers. Related research aims to identify subtypes of acute lymphoid leukemia to help better match patients to effective treatments.

What can data tell us about children’s cancer treatment, and how can we use this information to improve outcomes?

Richard Aplenc, MD, PhD, MSCE, Professor, uses electronic medical record data pooled by leading cancer centers to understand disparities in health care such as why black children with acute myeloid leukemia are more likely to develop or die from infections than white children with the same disease.

How can we help survivors of childhood cancer lead healthier lives?

Sogol Mostoufi-Moab, MD, MSCE, Assistant Professor, brings a unique perspective to the field of survivorship. The dual-certified pediatric oncologist and endocrinologist studies bone health in childhood cancer survivors with a goal of preventing future medical complications.

Which treatments are safest and most effective?

A large cancer clinical trials program offers options for families, many of whom cross state and country lines in search of hope. **Peter Adamson, MD**, Professor, chairs the Children’s Oncology Group, the national organization that oversees cancer clinical trials in children.



Get involved by contacting
Michal Greenberg
at michalg@upenn.edu
or (215) 573-2480.

Q&A with GI Nurse Navigator Patricia Gambino, MSN, RN

Years on the Job: 20

Patients per Rotation: 50+

What does a nurse navigator do?

Primarily, the role of a nurse navigator is to streamline and expedite patient appointments so that the patient sees the right physician at the right moment in the trajectory of their care. We also act as a resource to newly diagnosed patients and can help educate them about their specific disease. When appropriate, nurse navigators also serve as a referral to other members of the integrative team such as dietitians or social workers—maximizing the support that is available through Penn.



What is it like to be part of the Pancreatic Cancer Research Center?

It is exhilarating. The PCRC is truly interdisciplinary, with each member of the team playing an integral role in the care of the patient and learning from one another's expertise. Being part of such a vibrant team gives me optimism about the future of treating pancreatic cancer.

What do you say to someone who is just diagnosed?

When a person is first diagnosed with pancreatic cancer, they can be paralyzed with fear. Connecting them with reputable organizations dedicated to supporting and educating both the patient and their family is vital. The more patients understand their disease, the more they are able to make decisions that impact their plan of care.

What is the hardest part of your job?

The most difficult part of my job is knowing that there are many patients who will not survive their disease. I always appreciate how much research is being done to improve survival rates with the ultimate goal of curing pancreatic cancer. Each new advance gives me great hope for the future of treating this disease.

How are you involved in clinical trials?

It is an important part of my responsibility to know which trials are enrolling from among the pancreatic cancer population. Each day, I receive many calls regarding eligibility for specific trials and triaging them correctly can prevent patients from traveling for trials that are closed or for which they are ineligible.

What do you do in your spare time?

In my spare time, I like to travel, garden, read, and exercise. I truly believe in the importance of self-care when your job is such a stressful-yet-rewarding-one. Of course, hanging out with my six grandchildren brings me great joy!

Awards & Honors

Penn's Abramson Cancer Center was appointed to the **National Comprehensive Cancer Network** as its 28th member institution.

David A. Asch, MD, MBA, received the ACTS Distinguished Investigator Award for Translation into Public Benefit and Policy.

Shelley L. Berger, PhD, has been appointed Co-Leader of the Tumor Biology Program at the ACC.

Ari D. Brooks, MD, received Susan G. Komen's Jamie Brooke Lieberman Remembrance Award.

Saar I. Gill, MD, PhD, received the Mark Foundation's inaugural Emerging Leader Award.

F. Bradley Johnson, MD, PhD, received a University Foundation Award from the University of Pennsylvania.

Teresa Lawless, BSN, has been elected to Penn Medicine's Distinguished Nurse Academy.

Bruce Levine, MD, has been named the 2018-2020 President-Elect of the International Society of Cell and Gene Therapy.

Marco Ruella, MD, received one of this year's ASPIRE Awards from the Mark Foundation.

Kristy L. Weber, MD, has been named first female President of the American Academy of Orthopaedic Surgeons.

Three Abramson Cancer Center researchers received National Institute of Health Awards:

Michael Mitchell, PhD, New Innovator Award

Nicola J. Mason, BVetMed, PhD, Early Independence Award

Mark A. Sellmyer, MD, PhD, Early Independence Award

Eight Abramson Cancer Center faculty were among the Web of Science's 2018 Highly Cited Researchers:

Dennis Discher, PhD

Karen Glanz, PhD, MPH

Stephan Grupp, MD, PhD

Hakon Hakonarson, MD, PhD

Christopher Hunter, BSc, PhD

Carl June, MD

John D. Lambris, PhD

E. John Wherry, PhD

FDA Approvals in 2018

More and more, the Abramson Cancer Center is becoming synonymous with "FDA-approval."

In 2018, findings from clinical trials led by Penn Medicine faculty led to four new therapies being approved by the FDA expanding our arsenal in the fight against cancer.

Olaparib

BRCA+ Breast Cancer

Susan Domchek, MD | January 2018

Azedra

Pheochromocytoma & Paraganglioma

Daniel A. Pryma, MD | July 2018

Kymriah

Non-Hodgkin's Lymphoma


Stephen J. Schuster, MD | May 2018

Xospata

Acute Myeloid Leukemia

Alexander Perl, MD, MS | November 2018

It Takes a Collective Community to Fight Cancer – Thank You



At this year's **Melanoma Journal Club**, first-year Penn medical students heard from their fellow students and a panel of melanoma patients and family members on the latest in melanoma research and the patient experience. The annual club is made possible through the generous support of the **Peggy Spiegler Melanoma Research Foundation**.



The City of Philadelphia and Mayor Jim Kenney presented **Philly Fights Cancer** with an official citation in recognition of its critical fundraising efforts to benefit clinical trials and translational research at the Abramson Cancer Center.



John P. Plastaras, MD, and Neha Vapiwala, MD, a husband and wife duo, received the **HEADstrong Achievement Award** at the celebratory 9th annual Lime Light Gala held on March 15th. The ACC is grateful to HEADstrong for their dedicated partnership that provides local, complimentary housing to patients, emotional and financial support, as well meals and entertainment in HUP throughout the year.



Breakthrough Bike Challenge board members and Abramson Cancer Center leadership gathered to celebrate a five year fundraising total of over \$1,000,000 raised for cancer research at Penn.

Calendar of Events

17th Focus on Melanoma Patient Conference
Friday, May 17, 8:00 a.m.,
Hilton Philadelphia City Avenue

2019 Susan Fazio Melanoma Foundation Golf Outing
Monday, May 20, 11:30 a.m.,
North Hills, PA

Laudenbach Periodontal and Dental Implants – Cancer Research Fundraiser
Tuesday, May 28, 6:00 p.m., Yards Brewing Company, Philadelphia

5th Annual Steps to Cure Sarcoma 5K Run/1 Mile Walk
Sunday, June 2, 2019, 9:00 am.,
Wayne, PA

3rd Annual Golf for Rob Tournament Drive Out Melanoma
Friday, June 7, 11:00 a.m.,
Mt. Laurel, NJ

Peggy Spiegler Melanoma Research Foundation's 11th Annual Talk While You Walk/5K Run
Saturday, June 22, 9:00 a.m.,
Pennsauken, NJ

Tara Miller Melanoma Foundation's 6th Annual Make the Best of It Bash
Friday June 28, 7:00 p.m.,
Atlantic City, NJ

For more information, visit PennMedicine.org/Cancer/Events



REGISTER NOW

BREAKTHROUGH BIKE CHALLENGE

BENEFITING PENN MEDICINE'S ABRAMSON CANCER CENTER

SUNDAY, SEPTEMBER 15 2019
BERKS COUNTY, PA

BreakthroughBikeChallenge.org

GIVING TO THE ABRAMSON CANCER CENTER

Support the Abramson Cancer Center's mission to advance cancer research, education, and patient care—and fuel hope. Visit PennMedicine.org/Abramson/Donate or call (215) 898-0578.

For the latest information about cancer care and research, visit our award-winning internet resource, Oncolink, at oncolink.org.



Development Office
3535 Market Street, Suite 750
Philadelphia, PA 19104-3309
(215) 898-0578

FOR INFORMATION OR APPOINTMENTS
Call (800) 789-PENN (7366) or visit our website at PennMedicine.org/Abramson